Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Black Diamond Therapeutics, Inc. (BDTX) had Stock-Based Compensation of $10.63M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-69.68M |
|
-- |
|
-- |
|
$78.78M |
|
$-78.78M |
|
$9.11M |
|
$-69.68M |
|
$-69.68M |
|
$-69.68M |
|
$-69.68M |
|
$-69.68M |
|
$-69.68M |
|
$-78.78M |
|
$-78.44M |
|
55.03M |
|
55.03M |
|
$-1.27 |
|
$-1.27 |
|
| Balance Sheet Financials | |
$101.18M |
|
$1.39M |
|
$21.46M |
|
$122.64M |
|
$20.57M |
|
-- |
|
$18.78M |
|
$39.35M |
|
$83.29M |
|
$83.28M |
|
$83.28M |
|
56.65M |
|
| Cash Flow Statement Financials | |
$-62.30M |
|
$16.97M |
|
$25.55M |
|
$57.04M |
|
$37.26M |
|
$-19.79M |
|
|
Stock-Based Compensation |
$10.63M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.92 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-62.21M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-83.66% |
|
-83.66% |
|
-56.81% |
|
-83.66% |
|
$1.47 |
|
$-1.13 |
|
$-1.13 |
|